Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bcg vaccine-UMC Utrecht-COVID-19
- Development stage
- Unknown
- Lead developer
- University Medical Center Utrecht
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intracutaneous
01
Overview
BCG (Bacillus Calmette-Guérin) is a live attenuated vaccine derived from *Mycobacterium bovis*, traditionally used for tuberculosis prevention and bladder cancer treatment. In the context of the COVID-19 pandemic, UMC Utrecht and Radboudumc investigated its potential to provide non-specific protection against SARS-CoV-2 through a mechanism known as "trained immunity." This process involves the epigenetic and metabolic reprogramming of innate immune cells, such as monocytes and natural killer cells, to enhance their response to subsequent unrelated infections. The Phase 3 BCG-CORONA trial (part of the international BRACE trial) evaluated whether BCG vaccination could reduce absenteeism and severe illness among healthcare workers. However, results published in the New England Journal of Medicine in 2023 indicated that the vaccine did not significantly protect against symptomatic COVID-19 in this population.
- Other names
- Bacillus Calmette-Guérin vaccineBCG vaccine
02
Targets
NOD2 (Nucleotide-binding oligomerization domain-containing protein 2)
Beyond the preview
Go deeper on bcg vaccine-UMC Utrecht-COVID-19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bcg vaccine-UMC Utrecht-COVID-19.